Compare AFYA & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AFYA | NNNN |
|---|---|---|
| Founded | 1999 | 2021 |
| Country | Brazil | Germany |
| Employees | 9395 | 27 |
| Industry | Other Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2019 | N/A |
| Metric | AFYA | NNNN |
|---|---|---|
| Price | $14.51 | $10.00 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 125.4K | 44.9K |
| Earning Date | 05-08-2026 | 04-07-2026 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.43 | N/A |
| Revenue Next Year | $7.15 | N/A |
| P/E Ratio | ★ $9.30 | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.00 | $10.50 |
| 52 Week High | $16.47 | $55.65 |
| Indicator | AFYA | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 23.86 |
| Support Level | $14.24 | N/A |
| Resistance Level | $14.77 | $30.21 |
| Average True Range (ATR) | 0.42 | 2.12 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 29.14 | 17.53 |
Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergraduate, deriving key revenue provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).